Charles Schwab stock drops after revenue falls a bit shy of expectations, amid trading weakness

Deutschland Nachrichten Nachrichten

Charles Schwab stock drops after revenue falls a bit shy of expectations, amid trading weakness
Deutschland Neuesten Nachrichten,Deutschland Schlagzeilen
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 97%

Tomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter @TomiKilgore.

Shares of Charles Schwab Corp.

fell 1.5% toward a five-month low in premarket trading Monday, after the financial services and discount brokerage giant beat third-quarter profit expectations but fell a bit shy on revenue. Net income dropped to $1.02 billion, or 56 cents a share, from $1.88 billion, or 99 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of 77 cents beat the FactSet consensus of 74 cents. Revenue declined 16.3% to $4.606 billion, below the FactSet consensus of $4.

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

MarketWatch /  🏆 3. in US

Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

Stock Market Today: Dow Futures Edge Up; Investors Eye Lululemon, PfizerStock Market Today: Dow Futures Edge Up; Investors Eye Lululemon, PfizerCharles Schwab is set to report earnings this morning; Middle East is in focus
Weiterlesen »

Gen Z will take financial advice from AI, hope to retire by 61Gen Z will take financial advice from AI, hope to retire by 61Workers under 27 expect to retire earlier than older generations, according to a Charles Schwab survey.
Weiterlesen »

Novo Nordisk to buy hypertension treatment from for $1.3 billion from KBP BiosciencesNovo Nordisk to buy hypertension treatment from for $1.3 billion from KBP BiosciencesTomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter TomiKilgore.
Weiterlesen »

McKesson doesn’t expect Rite Aid’s bankruptcy to have much affect on profit outlook, liquidityMcKesson doesn’t expect Rite Aid’s bankruptcy to have much affect on profit outlook, liquidityTomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter TomiKilgore.
Weiterlesen »

BioNTech’s stock sinks after disclosing expected charge of up to nearly $1 billion resulting from Pfizer’s write offs of COVID productsBioNTech’s stock sinks after disclosing expected charge of up to nearly $1 billion resulting from Pfizer’s write offs of COVID productsTomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter TomiKilgore.
Weiterlesen »

Bitcoin’s surge gives a boost to crypto-related stocksBitcoin’s surge gives a boost to crypto-related stocksTomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter TomiKilgore.
Weiterlesen »



Render Time: 2025-02-27 02:00:03